Melissa Johnson, MD

Articles

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

December 23rd 2022

Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.

Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

December 16th 2022

Shared perspectives on the emerging strategies for the management of non–small cell lung cancer following the identification of KRAS/STK11, or KRAS/KEAP1 mutations.

Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

December 16th 2022

Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.

POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

December 9th 2022

A focused review of data from the POSEIDEN post-hoc analysis in patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated non–small cell lung cancer.

Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

December 9th 2022

Expert oncologists Melissa Johnson, MD, and Joshua Sabari, MD, discuss the occurrence of individual KRAS, STK11, or KEAP1 mutations in patients with non–small cell lung cancer and if there is a role for immunotherapy in the treatment of these patients.

The Exciting Future of NSCLC Treatment

November 23rd 2022

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

November 16th 2022

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

November 16th 2022

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

November 9th 2022

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

November 9th 2022

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

November 2nd 2022

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2nd 2022

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

November 2nd 2022

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non–small cell lung cancer.

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

October 26th 2022

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

October 26th 2022

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

October 19th 2022

Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

October 19th 2022

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

October 17th 2022

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

October 17th 2022

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

October 7th 2022

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.